AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02367664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine
Description: Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
Study NCT02367664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)
Description: inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
Study NCT03409276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: env (A,B,C,A/E)/gag (C) DNA Vaccine
Description: Administered by intramuscular injection in the deltoid.
Study NCT03409276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp120 (A,B,C,A/E) Protein Vaccine
Description: Administered by intramuscular injection in the deltoid.
Study NCT06751875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Patients are randomized to either receive lithium or not.
Study NCT01602536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation aides
Description: All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
Study NCT01602536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation aides
Description: All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
Study NCT01602536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twitter
Description: Twitter quit-smoking group
Study NCT00755989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine topical gel
Description: morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay
Study NCT00755989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: topical gel without morphine
Study NCT03409276 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
Study NCT03409276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
Study NCT03409276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Administered by intramuscular injection in the deltoid.
Study NCT00244504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxonidine
Description: moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
Study NCT00244504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxonidine
Description: moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
Study NCT03823118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1/Anlotinib
Description: Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
Study NCT04020991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep Study
Description: Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
Study NCT01108848 — intervention group
Intervention type: BIOLOGICAL
Intervention: Berinert® (C1 Esterase Inhibitor)
Description: Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
Study NCT03069482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Learn to Quit App
Description: A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
Study NCT03069482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
Study NCT03069482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
Study NCT03069482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
Study NCT03069482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
Study NCT03069482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical Coaching
Description: Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (\~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
Study NCT03069482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical Coaching
Description: Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (\~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
Study NCT03069482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCI QuitGuide App
Description: A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
Study NCT04575896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
Study NCT04537923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT04537923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (U100)
Description: Administered SC
Study NCT02346383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: preset program
Description: Change to different present program using epidural and peripheral lead to cover pain
Study NCT04377165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: This will provide the user with the newsfeed function and the addition of a gamification function
Study NCT04377165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsfeed function
Description: This will provide the user with reliable accurate information on the pandemic.
Study NCT01114854 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topiramate IR
Study NCT01114854 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topiramate ER
Study NCT04112004 — intervention group
Intervention type: OTHER
Intervention: Collecting sodium reports and outcome measures
Study NCT02794441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
Study NCT02794441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral solution
Study NCT04222348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850-2550 mg every 24h.
Study NCT04222348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850-2550 mg every 24h.
Study NCT04222348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir
Description: Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
Study NCT04222348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Detemir
Description: Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
Study NCT01367873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, matching number of placebo capsule(s) with active arm
Study NCT01367873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-3196
Description: Oral, capsule(s)
Study NCT02559674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
Study NCT02559674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
Study NCT02559674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
Study NCT00114868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Study NCT00540150 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)
Description: We treat each patient with mite-allergen following the two different protocols.
Study NCT03220269 — intervention group
Intervention type: OTHER
Intervention: Out-of-hospital cardiac arrest (OHCA)
Description: Data collection
Study NCT03220269 — intervention group
Intervention type: OTHER
Intervention: In-hospital cardiac arrest (IHCA)
Description: Data collection
Study NCT00114868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Study NCT01787617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Plus Resistance Training Group
Description: Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
Study NCT01787617 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
Study NCT02676167 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PrEP Intervention
Study NCT03894865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure1
Description: The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared
Study NCT03894865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure2
Description: Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
Study NCT00907153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 300 mcg by mouth once daily for 12 weeks
Study NCT02788305 — intervention group
Intervention type: DRUG
Intervention: Misoprostol
Description: Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
Study NCT02339506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosyntropin
Description: Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
Study NCT02339506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
Study NCT00907153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth once daily for 12 weeks
Study NCT02883114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
Study NCT02883114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
Study NCT02201069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching
Study NCT01043666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study NCT01043666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01043666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine ER
Description: oral
Study NCT00272168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maryland Program for Vocational Effectiveness
Description: psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
Study NCT00272168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Treatment for SMI
Description: Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
Study NCT02367911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551 Foam
Description: 122-0551 Foam applied twice daily to treat psoriasis
Study NCT02367911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam applied twice daily to treat psoriasis
Study NCT02730494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lcr Regenerans® vaginal capsules
Study NCT02730494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lcr Regenerans® vaginal tablet
Study NCT00976001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information, further rehabilitation, additional drugs to prevent recurrent stroke
Study NCT04966468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
Study NCT04966468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires.
Study NCT00581230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with RAMP
Description: inflatable positioning ramp
Study NCT00581230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy without RAMP
Description: Laryngoscopy without RAMP
Study NCT01353313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Study NCT01353313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Study NCT02780388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
Study NCT00609245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
Study NCT00609245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
Study NCT02780388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
Study NCT00976001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: As the general practitioner wants to do
Study NCT01543035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stop statin and switch to an antiretroviral drug with less impact on lipid metabolism
Description: Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin